LOGIN  |  REGISTER
Assertio
Cue Biopharma

iSpecimen to Participate in Maxim’s Healthcare IT Virtual Conference on June 1, 2023

May 23, 2023 | Last Trade: US$0.84 0.03 3.44

LEXINGTON, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that Tracy Curley, CEO of iSpecimen, will participate in the Healthcare IT Virtual Conference hosted by Maxim Group LLC (“Maxim”) and M-Vest, a division of Maxim, on Thursday, June 1, 2023.

Ms. Curley will participate in a fireside chat with Allen Klee, Research Analyst at Maxim, at 11:00 a.m. ET. To attend, please register here.

For more information about the conference, or to schedule a one-on-one meeting with iSpecimen’s management team, please contact your appropriate Maxim representative, or send an email to KCSA Strategic Communications at This email address is being protected from spambots. You need JavaScript enabled to view it..

About iSpecimen

iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit www.ispecimen.com.

For further information, please contact:

Investor Contact
KCSA Strategic Communications
Phil Carlson / Erika Kay
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contacts
KCSA Strategic Communications
Raquel Cona / Michaela Fawcett
This email address is being protected from spambots. You need JavaScript enabled to view it.

Viking Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page